Clinical trial NCT00206635 - References

Multiple Sclerosis — Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Citation(s)

•   Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study
  Analysis of clinical outcomes according to original treatment groups 16 years after the pivot
•   Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V; 16-Year Long-Term Follow-up Study Investigators
  Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to e
•   Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC; 16-Year Long Term Follow-up Study Investigators
  Relationship between early clinical characteristics and long term disability outcomes: 16 year coh
•   Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A; Investigators of the 16-Year Long-Term Follow-Up Study
  Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Ne

A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis

Details for clinical trial NCT00206635